The clinicopathological and prognostic significance of PSMD14 in cancers based on bioinformatics and meta-analysis

Aim: To evaluate the clinic-pathological features and prognostic value regarding PSMD14 in cancers. Materials & methods: Literature was gathered from public databases until 22 June 2023 to analyze data on survival rates and clinicopathological characteristics associated with PSMD14. TCGA and GEO data were also utilized for validation. Results: Eight reports on seven types of tumors showed that high PSMD14 expression was linked to poorer overall survival and disease-free survival. PSMD14 expression also correlated with larger tumor size, differentiation and metastasis, as well as the effectiveness of various chemotherapy drugs. Conclusion: PSMD14 could serve as a potential biomarker of poor prognosis in cancers, including lung cancer, head and neck squamous cell carcinoma, ovarian cancer, breast cancer and hepatocellular carcinoma. PLAIN LANGUAGE SUMMARY Cancer is harmful to human health. We need to find a marker that can help us identify and treat cancer. PSMD14 is one such marker. The expression of PSMD14 is higher in cancer tissues than in normal tissues. The expression of PSMD14 is associated with the sensitivity of cancer to anticancer drugs. Cancers with high PSMD14 expression tend to be more severe. Cancers with low expression of PSMD14 tend to have a longer survival time.